MRK vs NTLA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Intellia Therapeutics exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 1/9, indicating poor financial health and operational inefficiency. While the company maintains a strong liquidity position with a current ratio of 5.08 and low debt, it is plagued by massive operating losses (-428.86% margin) and a prohibitively high Price/Sales ratio of 26.08. Despite strong YoY revenue growth and positive analyst price targets, the combination of bearish insider selling and a long-term 5-year price decline of 78.8% suggests a high-risk speculative profile rather than a value investment.
Compare Another Pair
Related Comparisons
MRK vs NTLA: Head-to-Head Comparison
This page compares Merck & Co., Inc. (MRK) and Intellia Therapeutics, Inc. (NTLA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.